Tubulocystic renal cell carcinoma: Is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases

Virchows Archiv

Volumn 462, Issue 2, 2013, Pages 183-192

  Steiner, Petr ^a   Hora, Milan ^a   Stehlik, Jan ^a   Martinek, Petr ^a   Vanecek, Tomas ^a   Petersson, Fredrik ^a,b   Michal, Michal ^a   Korabecna, Marie ^a   Travnicek, Ivan ^a   Hes, Ondrej ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Angiogenic pathways; Antiangiogenic targeted therapy; Kidney; mRNA expression; Protein expression; Tubulocystic renal cell carcinoma

Indexed keywords

MESSENGER RNA; ANGIOGENESIS INHIBITOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; AKT GENE; AKT2 GENE; AKT3 GENE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; C JUN GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EGFR GENE; FEMALE; FGF2 GENE; FLT1 GENE; GENE; GENE EXPRESSION; GENE MUTATION; HIF 1ALPHA GENE; HIF 2ALPHA GENE; HIF GENE; HRAS GENE; HUMAN; HUMAN TISSUE; KDR GENE; KIDNEY CARCINOMA; MALE; METHYLATION; MITOGEN ACTIVATED PROTEIN KINASE GENE; MTOR GENE; ONCOGENE C FOS; PI3K GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PTEN GENE; RTK GENE; SIGNAL TRANSDUCTION; TP53 GENE; TUBULOCYSTIC RENAL CELL CARCINOMA; UPREGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A GEE; VHL GENE; CASE REPORT; DRUG EFFECT; GENETICS; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

MLCS; MLOWN;

EID: 84877136826     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1367-z     Document Type: Article

References (55)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. IARC, Lyon, p 359
2. Masson P (1956) Tumeurs Humaines Histologie, Diagnostics et Techniques, 2nd edn. Librairie Maloine, Paris, p 1214
3. Amin M, MacLennan G, Paraf F, Cheville J, Vieillefond A, Radhakrishnan A, Che M, Srigley J, Grignon D (2004) Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 29 cases of distinctive rare subtype of renal carcinoma. Mod Pathol 28(suppl):137A
4. Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, Vieillefond A, Paner GP, Stovsky M, Young AN, Srigley JR, Cheville JC (2009) Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol 33(3):384-392. doi: 10.1097/PAS.0b013e3181872d3f
5. Azoulay S, Vieillefond A, Paraf F, Pasquier D, Cussenot O, Callard P, Sibony M (2007) Tubulocystic carcinoma of the kidney: a new entity among renal tumors. Virchows Arch 451(5):905-909. doi: 10.1007/s00428-007-0483-7
6. Hora M, Urge T, Eret V, Stránský P, Klečka J, Kreuzberg B, Ferda J, Hyršl L, Breza J, Holečková P, Mego M, Michal M, Petersson F, Hes O (2010) Tubulocystic renal carcinoma: a clinical perspective. World J Urol 29:349-354. doi: 10.1007/s00345-010-0614-7
7. Mego M, Sycova-Mila Z, Rejlekova K, Rychly B, Obertova J, Rajec J, Hes O, Mardiak J (2008) Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report. Ann Oncol 19(9):1655-1656. doi: 10.1093/annonc/mdn408
8. Osunkoya AO, Young AN, Wang W, Netto GJ, Epstein JI (2009) Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney. Am J Surg Pathol 33(7):1103-1106. doi: 10.1097/PAS. 0b013e3181a13e7b
9. Yang XJ, Zhou M, Hes O, Shen S, Li R, Lopez J, Shah RB, Yang Y, Chuang ST, Lin F, Tretiakova MM, Kort EJ, Teh BT (2008) Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol 32(2):177-187. doi: 10.1097/PAS.0b013e318150df1d
10. Zhou M, Yang XJ, Lopez JI, Shah RB, Hes O, Shen SS, Li R, Yang Y, Lin F, Elson P, Sercia L, Magi-Galluzzi C, Tubbs R (2009) Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol 33(12):1840-1849. doi: 10.1097/PAS.0b013e3181be22d1
11. Négrier S, Raymond E (2011) Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 30(4):1791-1801. doi: 10.1007/s10637-011-9677-6
12. Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, Kim HL (2007) Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques 43(5):639-640, 642-633, 647
13. Nyhan MJ, El Mashad SM, O'Donovan TR, Ahmad S, Collins C, Sweeney P, Rogers E, O'Sullivan GC, McKenna SL (2010) VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin. Anal Cell Pathol (Amst) 33(3):121-132. doi: 10.3233/ACP-CLO-2010-0541
14. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
15. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, Moorman AF (2009) Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 37(6):e45. doi: 10.1093/nar/gkp045
16. Hes O, Michal M, Síma R, Vanecek T, Brunelli M, Martignoni G, Kuroda N, Alvarado Cabrero I, Perez-Montiel D, Hora M, Urge T, Dvorák M, Jarosová M, Yang X (2008) Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical, and genetic features. Virchows Arch 452(2):193-200. doi: 10.1007/s00428-007-0541-1
17. Ather MH, Masood N, Siddiqui T (2010) Current management of advanced and metastatic renal cell carcinoma. Urol J 7(1):1-9
18. Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl 2):14-22. doi: 10.1634/theoncologist.2011-S2-14
19. Rini BI (2009) Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115(10 Suppl):2306-2312. doi: 10.1002/cncr.24227
20. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB (2007) The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 13(2 Pt 2):758s-763s. doi: 10.1158/1078-0432.CCR-06-1986
21. Ohno Y, Izumi M, Tachibana M, Kawamura T, Yoshioka K, Aoyagi T, Ohori M, Namiki K, Sakamoto N, Nakagami Y, Hatano T, Akimoto S, Nishimura T (2008) Characterization and gene expression analysis of novel matched primary and metastatic renal cell carcinoma cell lines. Oncol Rep 20(3):501-509
22. Stewart GD, O'Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D (2011) What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol 8(5):255-265. doi: 10.1038/nrurol.2011.43
23. Takahashi M, Teh BT, Kanayama HO (2006) Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. J Med Invest 53(1-2):9-19
24. Krzyszto O (2008) Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis. Pol J Pathol 59(3):129-176
25. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11(16):5730-5739. doi: 10.1158/1078-0432.CCR-04-2225
26. Schuetz AN, Yin-Goen Q, Amin MB, Moreno CS, Cohen C, Hornsby CD, Yang WL, Petros JA, Issa MM, Pattaras JG, Ogan K, Marshall FF, Young AN (2005) Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 7(2):206-218. doi: 10.1016/S1525-1578(10)60547-8
27. Tickoo S, Westfall D, Reuter V (2010) Tubulocystic carcinoma. In: Amin MB, McKenney JS, Tickoo SK, Paner GP, Shen SS, Velazquez EF, Cubilla AL, Ro JY, Reuter VE (eds) Diagnostic pathology, genitourinary. Amirsys, Inc., Manitoba, pp 92-95
28. Tonini G, Fratto ME, Imperatori M, Pantano F, Vincenzi B, Santini D (2011) Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. Expert Rev Anticancer Ther 11(6):921-930. doi: 10.1586/era.11.63
29. Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, Miki T, Nakamura Y, Katagiri T (2006) Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol 29(4):799-827
30. Biró K, Küronya Z (2010) Recent advancements in the treatment of renal cell carcinoma - focus on international guidelines. Magy Onkol 54(4):369-376. doi: 10.1556/MOnkol.54.2010.4.11
31. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7(1):85-90. doi: 10.1038/ng0594-85
32. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, Miura T, Moriyama M, Nagashima Y, Nakatani Y, Kubota Y, Kondo K (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94(20):1569-1575
33. Linehan WM, Zbar B (2004) Focus on kidney cancer. Cancer Cell 6(3):223-228. doi: 10.1016/j.ccr.2004.09.006
34. Cheng L, Williamson SR, Zhang S, Maclennan GT, Montironi R, Lopez-Beltran A (2010) Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. Expert Rev Anticancer Ther 10(6):843-864. doi: 10.1586/era.10.72
35. Henske EP, Thorner P, Patterson K, Zhuang Z, Bernstein J (1999) Renal cell carcinoma in children with diffuse cystic hyperplasia of the kidneys. Pediatr Dev Pathol 2(3):270-274
36. Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, Benoît G, Jardin A, Bedossa P (2000) Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 436(4):351-356
37. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54(15):4233-4237
38. Kaelin WG (2009) Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115(10 Suppl):2262-2272. doi: 10.1002/cncr.24232
39. Haase VH (2006) Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291(2):F271-F281. doi: 10.1152/ajprenal.00071.2006
40. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19(48):5435-5443. doi: 10.1038/sj.onc.1203938
41. Black SM, DeVol JM, Wedgwood S (2008) Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation. Am J Physiol Cell Physiol 294(1):C345-C354. doi: 10.1152/ajpcell.00216.2007
42. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E (2005) Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46(1):31-36. doi: 10.1111/j.1365-2559.2005.02045.x
43. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281(36):25903-25914. doi: 10.1074/jbc.M603414200
44. Laderoute KR, Calaoagan JM, Gustafson-Brown C, Knapp AM, Li GC, Mendonca HL, Ryan HE, Wang Z, Johnson RS (2002) The response of c-jun/AP-1 to chronic hypoxia is hypoxia-inducible factor 1 alpha dependent. Mol Cell Biol 22(8):2515-2523
45. Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M (2001) HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life 52(1-2):49-53. doi: 10.1080/15216540252774766
46. Shibuya M (2001) Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 33(4):409-420
47. Müller JM, Krauss B, Kaltschmidt C, Baeuerle PA, Rupec RA (1997) Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. J Biol Chem 272(37):23435-23439
48. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, Yonezawa K (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278(18):15461-15464. doi: 10.1074/jbc.C200665200
49. Hadoux J, Vignot S, De La Motte RT (2010) Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol 4:143-154. doi: 10.4137/cmo.s4482
50. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5(6):379-385
51. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109(11):2257-2267. doi: 10.1002/cncr.22677
52. Masuda A, Kamai T, Abe H, Arai K, Yoshida K (2009) Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma? Biomed Res 30(3):171-176
53. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14(1):34-44
54. MacLennan GT, Farrow GM, Bostwick DG (1997) Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology 50(5):679-684. doi: 10.1016/S0090-4295(97)00335-X
55. Srigley JR, Eble JN (1998) Collecting duct carcinoma of kidney. Semin Diagn Pathol 15(1):54-67